Management and outcome in invasive and locally-advanced bladder cancer

Sunday, 26 March
12:00 - 14:00

**Location:** Room 16, Capital suite (level 3)

**Chair:** B. Malavaud, Toulouse (FR)

**Aims and objectives of this session**
MIBC is a multifaceted entity where one size no longer fits all, supporting the development of personalized and, in selected cases, organ-preserving strategies.

Are the advances in imaging, molecular biology, conservative surgery; medical oncology and radiotherapy strong enough to shift the current pre-eminence of the ablative approach toward a more integrated and conservative perspective? If yes, what are the ideal candidates?

- One size does not fit all and urologists are central to the development of personalized treatment in MIBC
- Patients selection is critical and based on advances in imaging, resection techniques and pathology
- Organ preservation is feasible in a significant proportion of patients
- Radical cystectomy and pre-emptive chemotherapy are essential to optimize results in aggressive conditions.

12:00 - 14:00

**Introduction**
B. Malavaud, Toulouse (FR)

12:00 - 14:00

**Cystectomy in the management of bladder invasive and locally-advanced bladder cancer**
M. Burger, Regensburg (DE)

12:00 - 14:00

**Case discussion on cystectomy in the management of bladder-invasive and locally-advanced bladder cancer**
B. Malavaud, Toulouse (FR)

12:00 - 14:00

**Bladder-sparing approaches to muscle invasive bladder cancer**
M. Burger, Regensburg (DE)

12:00 - 14:00

**Case discussion on bladder sparing approaches to muscle invasive bladder cancer**
B. Malavaud, Toulouse (FR)

12:00 - 14:00

**Cytotoxic chemotherapy in bladder cancer: Neoadjuvant and adjuvant setting and treatment of metastatic disease**
B. Malavaud, Toulouse (FR)